Working… Menu

Comparison of Two Treatment Strategies in Hypertensive Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00171444
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : November 8, 2011
Information provided by (Responsible Party):

Brief Summary:
The purpose of the study is to determine whether a specific training of General Practitioners (Family Physicians) regarding the new official guidelines for the treatment of hypertension results in a higher control of high Blood pressure in their patient population.

Condition or disease Intervention/treatment Phase
Hypertension Behavioral: Medical education Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4445 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: A 8-week Comparison, in a General Practice Setting, Between Two Treatment Strategies With Valsartan and Valsartan/HCTZ Aiming at Normalizing de Novo Hypertensive Patients Who Are Not Adequately Controlled With Their Monotherapy or Biotherapy Treatment or Experiencing Unacceptable Side-effects, According to Their Baseline Blood Pressure
Study Start Date : June 2004
Actual Primary Completion Date : May 2005
Actual Study Completion Date : May 2005

Resource links provided by the National Library of Medicine

Drug Information available for: Valsartan

Primary Outcome Measures :
  1. Blood pressure less than 140/90 mmHg in non-diabetic patients, or less than 130/80 mmHg in patients with diabetes or kidney disease, after 8 weeks

Secondary Outcome Measures :
  1. Change from baseline systolic blood pressure after 8 weeks
  2. Change from baseline diastolic blood pressure after 8 weeks
  3. Diastolic blood pressure less than 90 mmHg or reduction in diastolic blood pressure greater than 10 mmHg
  4. Systolic blood pressure less than 140 mmHg or reduction in diastolic blood pressure greater than 15 mmHg

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • • Male or female patients >18 years of age

    • Hypertension defined by MSDBP ≥ 90 and /or MSSBP ≥ 140 mmHg for untreated patients, patients on diet and exercise, patients on current anti-hypertensive monotherapy or bitherapy treatment who remain uncontrolled or patients experiencing unacceptable side-effects,

Exclusion Criteria:

  • • Severe hypertension, secondary hypertension, type 1 diabetes mellitus

    • History of congestive heart failure, unstable coronary insufficiency, life threatening arrhythmia, significant valvular disease, second or third degree heart block etc.
    • Other protocol-defined exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00171444

Sponsors and Collaborators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novatis Pharmaceuticals

Layout table for additonal information
Responsible Party: Novartis Identifier: NCT00171444     History of Changes
Other Study ID Numbers: CVAH631DFR06
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: November 8, 2011
Last Verified: September 2005
Keywords provided by Novartis:
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action